Amgen’s Kyprolis has beaten Janssen’s Velcade on progression-free survival in patients with relapsed or refractory multiple myeloma taking part in the Phase III Endeavor trial.
Read MoreFrench drugmaker Servier has presented late-stage data on Protelos, which shows that the drug reduced structural progression of osteoarthritis in knee joints by one-third.
Read MoreData presented at the International Breast Cancer Conference at St Gallen, Switzerland has shown that gene expression testing for early-stage breast cancer is working well in getting patients onto more appropriate treatment in Europe.
Read MoreSeattle Genetics and partner Takeda Pharmaceutical Co have presented two lots of promising data for brentuximab vedotin, the firms’ novel antibody-drug conjugate, in Hodgkin’s lymphoma and anaplastic large cell lymphoma.
Read More
